Ethical questions raised in search for Sardinian centenarians' secrets
By Stephanie Kirchgaessner,
The Guardian
| 08. 12. 2016
Untitled Document
There is something like gold flowing through the veins of 100-year-old Maria Tegas, and everyone wants a piece of the treasure.
The centenarian, who lives in a poor and remote area of central eastern Sardinia – in one of 14 villages known to geneticists and genealogists as the Blue Zone – has not had an easy life. Orphaned at the age of one, she remembers what it was like to go hungry, when homemade acorn bread was her main sustenance. As a young woman, she often walked 15 miles (24km) a day in steep and rocky terrain to bring food home to her six children.
“We lived like birds in the sky,” she says in a tiny whisper of a voice. Life got better, she says, when she began receiving welfare at the age of 50.
Tegas and hundreds of Sardinians like her have been considered a medical mystery since scientists started competing to find out why Blue Zone inhabitants have a life expectancy that is significantly higher than other Sardinians about 20 years ago.
For every 100,000...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...
By Isabel van Brugen, Newsweek | 06.05.2025
A U.S.-based biotech company has unveiled a new in vitro fertilization (IVF) option that allows parents to select embryos based on genetic markers tied to health and longevity.
DNA testing and analysis company Nucleus Genomics has announced the world's first...
By Jonathan D. Grinstein, PhD, Inside Precision Medicine | 06.03.2025
On Tuesday, 307 days after he was first admitted to Children’s Hospital of Philadelphia (CHOP), KJ Muldoon went home after being successfully treated with the first personalized CRISPR gene editing therapy. KJ, who was born with a serious and...